Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH -- Ignore unavailable to you. Want to Upgrade?

To: Swami who wrote (550)	2/11/1999 4:41:00 PM
From: TH	Read Replies (1) \| Respond to of 1084

I found nothing major in the report. It does appear that some patients in the December 1998 clinical trials have unfortunately died. It was determined by their physicians that their deaths were not related to ASTM products but rather were from complications from their original illness. I am not an expert in this area, but I assume that these early trials are with patients who are very sick and may have been considered for treatment with the ASTM process as a measure of last resort. I am assuming that a much higher percentage of these patients may be beyond the reach of any medical treatment and as a result would have died regardless of any measures. Hopefully in later trials the ASTM procedure will be used on a wider range of illness and may have a more beneficial impact. Long ASTM and regardless of the stock performance it saddens me to see that not all the patients in the trial could be saved. Thurston